This map shows the geographic impact of R M Sharkey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R M Sharkey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R M Sharkey more than expected).
This network shows the impact of papers produced by R M Sharkey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R M Sharkey. The network helps show where R M Sharkey may publish in the future.
Co-authorship network of co-authors of R M Sharkey
This figure shows the co-authorship network connecting the top 25 collaborators of R M Sharkey.
A scholar is included among the top collaborators of R M Sharkey based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with R M Sharkey. R M Sharkey is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
15 of 15 papers shown
1.
Juweid, Malik, George Hajjar, Rhona Stein, et al.. (2000). Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.. PubMed. 41(1). 93–103.45 indexed citations
2.
Behr, Thomas M., Torsten Liersch, Martin Béhé, et al.. (1999). Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.. PubMed. 5(10 Suppl). 3232s–3242s.42 indexed citations
Behr, Thomas M., Bernhard Wörmann, Martin Gramatzki, et al.. (1999). Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.. PubMed. 5(10 Suppl). 3304s–3314s.45 indexed citations
Juweid, Malik E., R M Sharkey, Abass Alavi, et al.. (1997). Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.. PubMed. 38(2). 257–60.16 indexed citations
Blumenthal, Rosalyn D., et al.. (1994). Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts.. PubMed. 54(1). 142–51.45 indexed citations
11.
Shih, Lisa B., David M. Goldenberg, Xuan Hong, et al.. (1991). Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier.. PubMed. 51(16). 4192–8.42 indexed citations
12.
Fand, I., R M Sharkey, & D M Goldenberg. (1990). Use of whole-body autoradiography in cancer targeting with radiolabeled antibodies.. PubMed. 50(3 Suppl). 885s–891s.6 indexed citations
13.
Goldenberg, David M., H Goldenberg, R M Sharkey, et al.. (1990). Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123I or 99mTc.. PubMed. 50(3 Suppl). 909s–921s.56 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.